After riding high for much of the pandemic, mRNA vaccine pioneers came down to earth in 2022. By mid-June, the share prices of both Massachusetts-based Moderna and Germany’s BioNTech had more than halved. But investors’ excitement was rekindled a few weeks ago when Moderna and partner Merck published a promising set of melanoma trial results. After five decades of failed attempts, cancer vaccines are set for a breakthrough.
在疫情期间大部分时间内持续上涨后，mRNA疫苗的先驱企业股票在2022年回到了地面上。截至去年6月中旬，总部位于马萨诸塞州的莫德纳(Moderna)和德国的BioNTech的股价都下跌了一半以上。但几周前，莫德纳及其合作伙伴默克公司(Merck)公布了一组很有前景的黑色素瘤试验疫苗，投资者的兴奋之情重新燃起。在经历了50年的失败尝试后，癌症疫苗即将取得突破。
您已阅读23%（607字），剩余77%（2005字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。